首页GBM • FRA
add
伊諾維奧製藥
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 2734.75万 | 175.54% |
净收入 | -2516.55万 | 25.83% |
净利润率 | — | — |
每股收益 | -0.89 | 42.95% |
息税折旧摊销前利润 | -2692.82万 | -10.37% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 8480.48万 | -49.36% |
总资产 | 1.07亿 | -44.56% |
负债总额 | 3351.94万 | -38.99% |
权益总额 | 7354.03万 | — |
发行在外的股份 | 2610.00万 | — |
市净率 | 1.35 | — |
资产回报率 | -56.77% | — |
资本回报率 | -69.87% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -2516.55万 | 25.83% |
来自运营的现金 | -2744.33万 | 5.73% |
投资现金 | 1407.78万 | 356.25% |
融资现金 | 66.06万 | -5.44% |
现金净变动 | -1270.49万 | 62.53% |
自由现金流 | -1747.04万 | 10.73% |
简介
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
CEO
成立时间
1999
员工数量
127
